Trend
DailyDowntrend (confirmed)
4 hourStrong Bullish
1 hourAscending Triangle
15 minBearish
5 minStrong Bearish
Daily trend turns up above $2.18
Key levels
Resistance$3.00
Resistance$2.76
Support$2.32
Support$2.02
Alector develops treatments for neurodegenerative disorders and is still in the testing phase of its drug pipeline. Its main candidate, nivisnebart, is an antibody intended to boost progranulin levels, and it is being developed with GSK for Alzheimer's at an early stage. The company also runs earlier-stage programs for Alzheimer's, Parkinson's, and Lewy body dementia, along with a brain-delivery technology platform.
Based on the company's 10-K filed Feb 25, 2026.
Nasdaq · Healthcare
SEPT Low Target
$3.00
SEPT Mid Target
$5.50
SEPT High Target
$8.00
Analyst Consensus
$5.50
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for ALEC.
Start Free Trial →Valuation Verdict
UNDERVALUED
Methods Used
Analyst Consensus
Fair Value
$5.50
0
Moat Score
NONE
1/9
Piotroski Score
-5.0
Altman Z-Score
Insider Signal
SELLING
0 buys / 8 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
MEDIUM
Signal: NEUTRAL
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Rosenthal Arnon | director officer | Buy | 217,500 | - | Oct 14, 2026 |
| Berkley Neil Lindsay | officer | Buy | 44,567 | - | Oct 14, 2026 |
| Wong-Sarad Grace | officer | Buy | 55,555 | - | Oct 14, 2026 |
| Wong-Sarad Grace | officer | Sale | 3,475 | $7K | Jun 3, 2026 |
| Rosenthal Arnon | director officer | Sale | 87,216 | $172K | Jun 2, 2026 |
| Wong-Sarad Grace | officer | Sale | 5,709 | $11K | Jun 2, 2026 |
| Berkley Neil Lindsay | officer | Sale | 19,360 | $38K | Jun 2, 2026 |
| SCHELLER RICHARD H | director | Buy | 10,833 | - | Jun 1, 2026 |
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
-79.1%
3yr Revenue CAGR
-46.0%
EPS Growth YoY
-13.01%
FCF Growth YoY
20.4%
Revenue Trend
DECLINING
SEPT Investing tracks real-time dark pool institutional trades for ALEC, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 14:37:59 | $2.62 | 1,070 | $$3K | MIDPOINT |
| 14:37:59 | $2.62 | 1,400 | $$4K | BUY |
| 14:19:28 | $2.52 | 5,486 | $$14K | SELL |
| 14:19:11 | $2.52 | 4,719 | $$12K | SELL |
| 21:03:02 | $2.68 | 6,000 | $$16K | BUY |
5 dark pool trades shown · $$48K preview volume
Real-time institutional flow, block trades, and net positioning
SEPT's Trading AI has generated a free, downloadable PDF research report for Alector, Inc. (ALEC) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →Alector, Inc. (ALEC) is at $2.58, down 2.09% (-$0.05) at the Nov 12, 2026 close.
Latest ALEC news — Nov 6, 2026: Alector Posts Q3 2026 Results
The average analyst price target for ALEC is $5.50, ranging from $3 to $8, based on 2 analysts. Latest: HC Wainwright & Co. maintains on Oct 15, 2026.
Analyst ratings for ALEC: 1 Buy, 3 Hold, 0 Sell — consensus Hold.
ALEC last reported on Nov 5, 2026: EPS $1.11 vs -$0.23 expected — a beat of 582.6%.
ALEC does not currently pay a dividend.
Support: $2.32, $2.02, $1.72. Resistance: $2.76, $3.00, $3.40.
Insider activity: SELLING, 0 buys and 8 sells in the last 90 days.
Nov 6, 2026: Alector Posts Q3 2026 Results